ALZAMEND NEURO, INC. Stockholders' Equity before Treasury Stock
ALZAMEND NEURO, INC. (ALZN) had Stockholders' Equity before Treasury Stock of $2.20 million as of 2026-01-31, per its 10-Q filed 2026-03-11.
Financial Statements › Notes › Equity
us-gaap:StockholdersEquityBeforeTreasuryStock · last filed 2026-03-11
- 2026-01-31: Stockholders' Equity before Treasury Stock $2.20M.
- 2025-10-31: Stockholders' Equity before Treasury Stock $4.40M.
- 2025-07-31: Stockholders' Equity before Treasury Stock $5.30M.
- 2025-01-31: Stockholders' Equity before Treasury Stock $3.40M.
| Period end | Stockholders' Equity before Treasury Stock |
|---|---|
| 2026-01-31 | $2.20M 10-Q · filed 2026-03-11 |
| 2025-10-31 | $4.40M 10-Q · filed 2025-12-09 |
| 2025-07-31 | $5.30M 10-Q · filed 2025-09-10 |
| 2025-01-31 | $3.40M 10-Q · filed 2025-03-10 |
| 2024-10-31 | $3.80M 10-Q · filed 2024-12-11 |
| 2024-07-31 | $1.20M 10-Q · filed 2024-09-11 |
| 2024-01-31 | $4.30M 10-Q · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |